Nothing Special   »   [go: up one dir, main page]

ES2624961T3 - Síntesis de productos de péptido que contienen imida cíclica - Google Patents

Síntesis de productos de péptido que contienen imida cíclica Download PDF

Info

Publication number
ES2624961T3
ES2624961T3 ES14710918.5T ES14710918T ES2624961T3 ES 2624961 T3 ES2624961 T3 ES 2624961T3 ES 14710918 T ES14710918 T ES 14710918T ES 2624961 T3 ES2624961 T3 ES 2624961T3
Authority
ES
Spain
Prior art keywords
formula
optionally
indicates
asymmetric
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14710918.5T
Other languages
English (en)
Inventor
Bernd Henkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of ES2624961T3 publication Critical patent/ES2624961T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30—Low-molecular-weight compounds
    • C08G18/38—Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3819—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
    • C08G18/3842—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing heterocyclic rings having at least one nitrogen atom in the ring
    • C08G18/3844—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing heterocyclic rings having at least one nitrogen atom in the ring containing one nitrogen atom in the ring
    • C08G18/3846—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing heterocyclic rings having at least one nitrogen atom in the ring containing one nitrogen atom in the ring containing imide groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Un método de síntesis de un producto de péptido que comprende al menos un grupo de imida cíclica de fórmula (I) o una sal o solvato del mismo:**Fórmula** en la que R1 es un puente de uno o dos átomos de longitud, R2 es un aminoácido cadena lateral, * indica un átomo de C asimétrico, y (*) indica un átomo de C opcionalmente asimétrico, que comprende las etapas: (a) acoplar un elemento estructural de sí ntesis de fórmula (II):**Fórmula** en la que X es un grupo protector de amino lábil a bases, Y es un grupo carboxi o carboxamido sin proteger, * indica un átomo de C asimétrico, y Z es un grupo carboxi, a un producto de péptido de fórmula (III)**Fórmula** en la que R2' es una cadena lateral de aminoácido opcionalmente protegida, R3 es un resto peptídico, y (*) indica un átomo de C opcionalmente asimétrico en condiciones en las que el grupo de imida cíclica de fórmula (I) se forma y en las que las condiciones de acoplamiento comprenden un tiempo de reacción de al menos 12 h, una temperatura de entre 15 y 40 ºC, adición repetida de reactivos de acoplamiento tales como TBTU o HBTU con DIPEA o HOBt/DIC y dimetilformamida (DMF) como disolvente orgánico (b) escindir el grupo protector de amino X, en el que dicha etapa (b) no se lleva a cabo con piperidina como agente desprotector, (d) opcionalmente purificar el producto de péptido (I). 30 (c) opcionalmente continuar la síntesis de péptidos, y

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES14710918.5T 2013-03-21 2014-03-19 Síntesis de productos de péptido que contienen imida cíclica Active ES2624961T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13160380 2013-03-21
EP13160380 2013-03-21
PCT/EP2014/055511 WO2014147129A1 (en) 2013-03-21 2014-03-19 Synthesis of cyclic imide containing peptide products

Publications (1)

Publication Number Publication Date
ES2624961T3 true ES2624961T3 (es) 2017-07-18

Family

ID=47900953

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14710918.5T Active ES2624961T3 (es) 2013-03-21 2014-03-19 Síntesis de productos de péptido que contienen imida cíclica

Country Status (11)

Country Link
US (1) US10450343B2 (es)
EP (1) EP2976325B1 (es)
CN (1) CN105102427B (es)
AU (1) AU2014234314B2 (es)
CA (1) CA2907521C (es)
DK (1) DK2976325T3 (es)
ES (1) ES2624961T3 (es)
HU (1) HUE033371T2 (es)
MX (1) MX365465B (es)
SG (1) SG11201506885UA (es)
WO (1) WO2014147129A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018032521A1 (zh) * 2016-08-19 2018-02-22 深圳市健元医药科技有限公司 一种利拉鲁肽的合成方法

Family Cites Families (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906031A (en) 1971-03-15 1975-09-16 Research Corp Novel 9-fluorenylmethoxycarbonyl compounds
US3835175A (en) 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
DE3542442A1 (de) 1985-11-30 1987-06-04 Hoechst Ag Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
US5175254A (en) 1988-09-24 1992-12-29 Societe D'expansion Scientifque Expansia Solid phase peptide synthesis using a polyacrylic support in aqueous solution
GB8913089D0 (en) 1989-06-07 1989-07-26 Ciba Geigy Japan Ltd Novel endothelin derivative
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5169932A (en) 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5580957A (en) 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
EP0445801A3 (en) 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
DE4014655A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Peptidamide, verfahren zu deren herstellung und diese enthaltende mittel als fibrin/thrombin-gerinnungsinhibitoren
TW295589B (es) 1990-08-30 1997-01-11 Hoechst Ag
US6040423A (en) 1990-08-31 2000-03-21 Gsellschaft Fur Biotechnologische Forschung Mbh (Gbf) Process for synthesis of peptides
IL101074A (en) 1991-03-14 1997-09-30 Salk Inst For Biological Studi GnRH ANALOGS AND THEIR PREPARATION
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
US5576296A (en) 1991-05-15 1996-11-19 Aktiebolaget Astra Galanin antagonist
GB9112825D0 (en) 1991-06-14 1991-07-31 Ici Plc Process for making peptides
US6028168A (en) 1991-08-09 2000-02-22 Winfried Kolbeck Lanthionine bridged peptides
CA2115246A1 (en) 1991-08-09 1993-02-18 Murray Goodman Lanthionine bridged peptides
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
EP0602194A1 (en) 1991-12-18 1994-06-22 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
DE69334148T2 (de) 1992-03-06 2008-02-21 Innogenetics N.V. HIV-Peptide
WO1993024526A1 (en) 1992-05-28 1993-12-09 Centocor, Inc. Peptide inhibitors of selectin binding
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
IE921942A1 (en) 1992-06-16 1993-12-29 Gary A Siwruk John S Eynon Liquid phase synthesis of peptides and peptide derivatives
WO1994005314A1 (en) 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5563032A (en) 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
US5736315A (en) 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE4244565A1 (de) 1992-12-30 1994-07-07 Forssmann Wolf Georg Verfahren und Anwendung des LPAP (Lymphocytoma Proliferation Activating Peptide
DK0611774T3 (da) 1993-02-19 1999-11-15 Hoffmann La Roche Racemiseringsfri fremstilling af amider og peptider i nærværelse af katalytiske mængder af en N-hydroxyforbindelse
JPH06256384A (ja) 1993-02-26 1994-09-13 Shimadzu Corp クリーベイジ装置
GB9319776D0 (en) 1993-09-24 1993-11-10 Medical Res Council Azapeptide synthesis
US6165778A (en) 1993-11-02 2000-12-26 Affymax Technologies N.V. Reaction vessel agitation apparatus
US5503805A (en) 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
EP0726906A4 (en) 1993-11-02 1998-10-07 Affymax Tech Nv THE SYNTHESIS AND EXAMINATION OF MOLECULAR DIVERSITY
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE4341471A1 (de) 1993-12-02 1995-06-08 Schering Ag Tumor-Nekrose-Faktor-alpha-inaktivierende CDR-Peptide
US5502165A (en) 1994-04-04 1996-03-26 Merck & Co., Inc. Process for peptide segment condensation
US5614608A (en) 1995-01-20 1997-03-25 Selectide Corporation Apparatus and method for multiple synthesis of organic compounds on polymer support
CA2215737A1 (en) 1995-04-28 1996-10-31 Koichi Kato Lh-rh receptor antagonists
GB9511474D0 (en) 1995-06-07 1995-08-02 Ciba Geigy Ag Antiviral peptoid compounds
DE19534988A1 (de) 1995-09-21 1997-03-27 Forssmann Wolf Georg Verfahren zur Herstellung und Anwendung synthetischer, biotinylierter Peptide
DE19543628A1 (de) 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
JP4405594B2 (ja) 1996-09-09 2010-01-27 ジーランド ファーマ アクティーゼルスカブ 改良型固相ペプチド合成及びかかる合成において利用するための試薬
NZ334595A (en) 1996-09-09 2000-08-25 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
JP2000507274A (ja) 1997-01-21 2000-06-13 マックス―プランク―ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・アインゲトラーゲナー・フェアアイン・ベルリン キャリヤーペプチドとしてのｉｇａ１プロテアーゼフラグメント
EP1950223A3 (en) 1998-03-09 2009-05-13 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1117677B1 (en) * 1998-09-29 2003-11-12 Statens Serum Institut Ligand presenting assembly (lpa), method of preparation and uses thereof
JP3786533B2 (ja) 1998-11-12 2006-06-14 善彦 西村 ペプチド及び骨形成促進剤
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
CA2354766A1 (en) 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
FR2792631B1 (fr) 1999-04-21 2004-03-19 Pasteur Institut Support solide fonctionnalise pour la synthese de composes comportant au moins une fonction alpha oxoaldehyde et ses applications.
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
ATE264870T1 (de) 2000-01-27 2004-05-15 Lilly Co Eli Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
US6476186B1 (en) 2000-05-23 2002-11-05 Institute Of Nuclear Energy Research Process for preparing octreotide and derivatives thereof
JP2004510703A (ja) 2000-06-14 2004-04-08 メダレックス，インコーポレイティド 酵素−分解性プロドラッグ化合物
US20020058788A1 (en) 2000-08-25 2002-05-16 Sheppeck James E. Facile deprotection of Fmoc protected amino groups
NO314588B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
AU2002227925A1 (en) 2000-11-14 2002-05-27 Ipf Pharmaceuticals Gmbh Human beta-defensin-3
WO2002053606A1 (en) 2001-01-04 2002-07-11 Council Of Scientific And Industrial Research A new linker based solid support for peptide and small molecule organic synthesis
GB0105069D0 (en) 2001-03-01 2001-04-18 Univ Ulster The Modified peptide
US20090281032A1 (en) 2001-03-01 2009-11-12 Peter Raymond Flatt Modified CCK peptides
BR0101088A (pt) 2001-03-19 2003-03-18 Biolab Sanus Farmaceutica Ltda Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório.
WO2002083606A1 (en) 2001-04-17 2002-10-24 University Of Alberta A linker system for the synthesis and screening of combinatorial libraries of polyamine derivatives on water compatible supports
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
FR2825095B1 (fr) 2001-05-28 2003-09-26 Dev Des Antigenes Combinatoire Dispositif de presentation de polypeptides, utilisable comme "puce" pour la detection miniaturisee de molecules
AU2002326103A1 (en) 2001-08-24 2003-03-10 University Of British Columbia Solid-phase synthesis of oligosaccharides and glycopeptides using glycosynthases
IL162780A0 (en) 2002-04-11 2005-11-20 Kenji Kangawa Method for producing modified peptide
US6809190B2 (en) 2002-04-24 2004-10-26 Credia Japan Co., Ltd. Functional peptide nucleic acid and its production method
EP1504022B1 (en) 2002-05-03 2006-10-11 Avecia Limited Process for the synthesis of peptide amides by side-chain attachment to a solid phase
GB0210183D0 (en) 2002-05-03 2002-06-12 Avecia Ltd Process
US20040018561A1 (en) 2002-05-10 2004-01-29 Decrescenzo Gary A. Peptide compounds and their use as protease substrates
ES2195787B1 (es) 2002-05-20 2005-06-01 Diverdrugs, S.L. Compuestos capaces de bloquear la respuesta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, un metodo para su obtencion y composiciones que los continen.
ES2299749T3 (es) 2002-08-09 2008-06-01 Astellas Pharma Europe B.V. Compuestos que se unen a p-selectina.
DE60330182D1 (de) 2002-09-08 2009-12-31 Applera Corp Festphasengebundene PNA-Dimere und deren Synthese
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
EP1445260A1 (de) 2003-02-04 2004-08-11 Jerini AG Verfahren zur Immobilisierung von chemischen Verbindungen an Festphasen
DK1613409T3 (da) 2003-04-08 2019-09-30 Novo Nordisk As Regenerering af kromatografiske stationære faser
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
US20060167224A1 (en) 2003-04-15 2006-07-27 Credia Japan Co., Ltd. Novel functional peptide nucleic acid and process for producing the same
WO2004105685A2 (en) 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
US7414106B2 (en) 2003-06-19 2008-08-19 Lawrence Livermore National Security, Llc Synthesis of peptide α-thioesters
US7902488B2 (en) 2003-06-23 2011-03-08 Cem Corporation Microwave-assisted peptide synthesis
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
ATE437181T1 (de) 2003-08-21 2009-08-15 Novo Nordisk As Reinigung glucagonähnlicher peptide
ES2295961T3 (es) 2003-12-31 2008-04-16 F. Hoffmann-La Roche Ag Proceso para la sintesis peptidica utilizacndo una cantidad reducida de agente de desproteccion.
FR2864830B1 (fr) 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
EP1713723A2 (en) * 2004-01-14 2006-10-25 William Marsh Rice University Fullerene based amino acids
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US20080200648A1 (en) 2004-07-16 2008-08-21 Lonza Ag Method of Peptide Synthesis
WO2006040037A1 (en) 2004-10-12 2006-04-20 F. Hoffmann-La Roche Ag Solid phase peptide sythesis
US8435800B2 (en) 2004-11-22 2013-05-07 Biosight Ltd. Activated labeling reagents and methods for preparing and using the same
US7745570B2 (en) 2004-12-17 2010-06-29 Kansas State University Research Foundation PH dependent adhesive peptides
CN100540565C (zh) 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
BRPI0609555A2 (pt) 2005-04-08 2010-04-13 Lonza Ag sìntese de peptìdeo de alfa-espirais sobre resina peg
ES2332666T3 (es) 2005-05-04 2010-02-10 Lonza Ag Timosina alfa1 unida a fase solida y metodo de sintesis.
CN1298732C (zh) 2005-05-17 2007-02-07 南京工业大学 多肽微波固相合成法
JP2008542292A (ja) 2005-05-26 2008-11-27 ブリストル−マイヤーズ スクイブ カンパニー Ｎ末端修飾ｇｌｐ−１受容体モジュレーター
CA2618494A1 (en) 2005-09-14 2007-03-22 Novetide, Ltd. Process for production of bivalirudin
DK1965823T3 (en) 2005-11-04 2016-08-22 Glaxosmithkline Llc Corp Service Company Methods of administering hypoglycemics
CN100374462C (zh) 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
US8058394B2 (en) 2006-03-29 2011-11-15 Otsuka Chemical Co., Ltd. Method for production of peptide thioester compound
ES2283212B1 (es) 2006-03-31 2008-08-16 Lipotec S.A. Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas.
WO2007113386A1 (en) 2006-03-31 2007-10-11 Karyon-Ctt Ltd Peptide conjugates
FI20065208A0 (fi) 2006-03-31 2006-03-31 Karyon Oy Peptidikonjugaatteja
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
GB2440388A (en) 2006-06-30 2008-01-30 Ucl Biomedica Plc Methods of linking a carbohydrate or polyalkylene oxide to a protein, precursors and the resultant products
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
WO2008044890A1 (en) 2006-10-12 2008-04-17 Dong Kook Pharm. Co., Ltd A method for preparing peptides using by solid phase synthesis
ES2322882B1 (es) 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1923397B1 (en) 2006-11-14 2009-10-28 NERVIANO MEDICAL SCIENCES S.r.l. Fluorinated amino acids and peptides
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2094721B1 (en) 2006-12-14 2018-02-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008109079A2 (en) 2007-03-01 2008-09-12 Novetide, Ltd. High purity peptides
WO2008137165A1 (en) 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AU2008271608A1 (en) 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
CN101357937B (zh) 2007-07-31 2012-11-07 上海苏豪逸明制药有限公司 固相多肽合成阿托西般的制备方法
CN101357938B (zh) 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
WO2009059002A2 (en) * 2007-10-30 2009-05-07 The Regents Of The University Of Michigan Office Of Technology Transfer Macrocyclization of compounds from solid support using thioesterases
AU2008334783A1 (en) 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
RU2461564C2 (ru) 2008-02-06 2012-09-20 Байокон Лимитид Способ очистки циклического или нециклического пептида
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
CN101525368B (zh) 2008-03-06 2012-05-30 海南建邦制药科技有限公司 一种多肽合成脱保护剂
CN101525370A (zh) 2008-03-06 2009-09-09 海南建邦制药科技有限公司 一种新型高效多肽合成缩合剂
CN101255191A (zh) 2008-03-12 2008-09-03 中国药科大学 微波促进固相合成胰高血糖素样肽-1(glp-1)类似物及其应用
NZ589365A (en) 2008-04-24 2013-06-28 Therimunex Pharmaceuticals Inc Peptidyl diacylglycerides
WO2009138488A1 (en) 2008-05-15 2009-11-19 Novo Nordisk A/S Purification of peptides prepared by solid phase synthesis
CN102123723B (zh) 2008-06-17 2016-05-25 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
HUE028072T2 (en) 2008-06-17 2016-11-28 Univ Indiana Res & Tech Corp GIP-based agonists for the treatment of metabolic disease and obesity
EP2334314A4 (en) 2008-09-03 2012-03-21 Scinopharm Taiwan Ltd PROCESS FOR THE PREPARATION OF PRAMLINTIDE
BRPI0918838A2 (pt) 2008-09-22 2015-12-08 Aileron Therapeutics Inc processos para preparação de composições de polipeptídeos purificados
TW201012829A (en) 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
MX2011005965A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
RU2011125366A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
MX2011006313A (es) 2008-12-15 2011-09-27 Zealand Pharma As Analogos de glucagon.
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
CN101463078B (zh) 2009-01-12 2011-07-27 华东师范大学 一种Exendin-4衍生物及其固相化学合成
CN101463081B (zh) 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物
CN101538324B (zh) 2009-01-13 2013-01-16 深圳翰宇药业股份有限公司 一种制备艾塞那肽的方法
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US20120021029A1 (en) 2009-04-17 2012-01-26 Lipotec, S.A. Peptides used in the treatment and/or care of the skin and/or hair and their use in cosmetic or pharmaceutical compositions
CN101555274B (zh) 2009-05-15 2013-08-21 海南双成药业股份有限公司 一种多肽固相合成比法卢定粗品的制备方法
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
SI2454282T1 (sl) 2009-07-13 2015-06-30 Zealand Pharma A/S Acilirani glukagonski analogi
WO2011009626A1 (en) 2009-07-24 2011-01-27 Lipotec, S.A. Compounds which inhibit muscle contraction
ES2358829B1 (es) 2009-10-23 2012-06-25 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosméticas o farmacéuticas.
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
IN2012DN06437A (es) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
WO2011107447A1 (en) 2010-03-01 2011-09-09 Novo Nordisk A/S Preparative rp-hplc method for purifying peptides
CN102918055B (zh) 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
US8620595B2 (en) 2010-03-26 2013-12-31 University Of Manitoba Methods for determining the retention of peptides in reverse phase chromatography using linear solvent strength theory
CN102918177B (zh) 2010-05-31 2015-09-09 株式会社捷太格特 覆盖部件的制造方法
JP5702376B2 (ja) 2010-06-01 2015-04-15 本田技研工業株式会社 Ｄｃ／ｄｃコンバータの制御装置
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN101906150B (zh) 2010-06-28 2013-01-09 上海昂博生物技术有限公司 一种比法卢定的制备方法
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
JP5579939B2 (ja) 2010-10-29 2014-08-27 ロンザ リミテッド ジケトピペラジン形成ジペプチジルリンカー
SG191194A1 (en) 2010-12-22 2013-07-31 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
WO2012085279A2 (en) 2010-12-23 2012-06-28 Universiteit Gent Method for cross-linking peptides
CN102643339B (zh) 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
CN102174082B (zh) 2011-02-23 2014-08-27 上海昂博生物技术有限公司 一种艾塞那肽的制备方法
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN102786590A (zh) 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
US8933196B2 (en) 2011-05-20 2015-01-13 National Central University Peptide chromatographic purification assisted by combining of solubility parameter and solution conformation energy calculations
CN102286076B (zh) 2011-06-23 2014-03-12 成都圣诺科技发展有限公司 比伐卢定的制备方法
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
UA115542C2 (uk) 2011-12-23 2017-11-27 Іпсен Мануфекчерінг Айрленд Лімітед Процес синтезу терапевтичних пептидів
CN102411801A (zh) 2011-12-27 2012-04-11 湖南超氏信息集成有限公司 一种挂起排队方法
CN103242443A (zh) 2012-02-06 2013-08-14 长春百克生物科技股份公司 一种胸腺素α1及其类似物的制备方法
CN102584944B (zh) 2012-02-06 2014-12-17 成都圣诺生物科技股份有限公司 一种依非巴特的制备方法
CN102558338B (zh) 2012-02-10 2014-09-17 深圳翰宇药业股份有限公司 一种合成利西拉来的方法
CN102584982B (zh) 2012-02-10 2014-02-05 深圳翰宇药业股份有限公司 一种纯化固相合成利拉鲁肽粗肽的方法
KR102113998B1 (ko) 2012-04-16 2020-05-25 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 피부 및／또는 점막의 치료 및／또는 관리용 화합물 및 미용적 또는 약학적 조성물에서의 이의 용도
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
CA2873452A1 (en) 2012-05-16 2013-11-21 Noxxon Pharma Ag Enzymatic synthesis of l-nucleic acids
CN102875663B (zh) 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 利西拉来的纯化方法
EP2950904A1 (en) 2013-01-29 2015-12-09 Neuland Health Sciences Private Limited Purification of organic compounds using surrogate stationary phases on reversed phase columns
CN103965285B (zh) 2013-02-06 2016-12-28 北京大学 一种以超顺磁纳米颗粒为固相进行多肽合成及同步构建多肽磁纳米探针的方法
CN103333237B (zh) 2013-05-07 2015-03-11 海南双成药业股份有限公司 一种固相片段法合成艾塞那肽
SG11201600272WA (en) 2013-07-15 2016-02-26 Univ North Carolina State Protease-resistant peptide ligands
US9263194B2 (en) 2013-09-06 2016-02-16 Gwangju Institute Of Science And Technology Porphyrin-peptoid conjugate and the preparation process thereof
US9605344B2 (en) 2013-09-15 2017-03-28 Stc.Unm Method for atomic layer deposition
CN103536912B (zh) 2013-09-30 2015-05-13 重庆理工大学 一种猪圆环病毒2型表位肽疫苗及其制备方法
CN103613655B (zh) 2013-11-20 2015-05-13 陕西东大生化科技有限责任公司 一种低成本纯化艾塞那肽的方法
JP6633523B2 (ja) 2013-12-01 2020-01-22 ユニバーシティ オブ コペンハーゲン Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
HU230584B1 (hu) 2014-02-28 2017-01-30 Szegedi Tudományegyetem Eljárás peptidek előállítására
CN104086631A (zh) 2014-07-10 2014-10-08 成都天台山制药有限公司 卡贝缩宫素和制法
RU2696276C2 (ru) 2014-08-07 2019-08-01 Ф. Хоффманн-Ля Рош Аг Способы получения аналогов окситоцина
EP3204414B1 (en) 2014-10-07 2024-12-04 Ann and Robert H. Lurie Children's Hospital of Chicago Novel anti-nodal antibodies and methods of using same
CN105585612B (zh) 2014-10-20 2020-05-05 北京益生康华医药技术有限公司 八肽修饰的地塞米松、制备、纳米结构和应用
US10344069B2 (en) 2014-10-31 2019-07-09 Auro Peptides Ltd. Process for the preparation of liraglutide
WO2016084100A2 (en) 2014-11-26 2016-06-02 Alaparthi Lakshmi Prasad Novel and efficient method for large scale synthesis of romidepsin
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
CN105111303B (zh) 2015-06-23 2019-07-26 济南康和医药科技有限公司 一种固液结合制备利拉鲁肽的方法
EP3433268B1 (en) 2016-03-23 2021-07-28 Bachem Holding AG Purification of glucagon-like peptide 1 analogs

Also Published As

Publication number Publication date
CN105102427B (zh) 2018-09-07
EP2976325A1 (en) 2016-01-27
US10450343B2 (en) 2019-10-22
EP2976325B1 (en) 2017-03-01
MX2015013463A (es) 2016-06-21
DK2976325T3 (en) 2017-06-06
CA2907521A1 (en) 2014-09-25
SG11201506885UA (en) 2015-09-29
CN105102427A (zh) 2015-11-25
HUE033371T2 (en) 2017-11-28
CA2907521C (en) 2021-04-13
WO2014147129A1 (en) 2014-09-25
AU2014234314B2 (en) 2018-02-15
US20160289263A1 (en) 2016-10-06
AU2014234314A1 (en) 2015-10-01
MX365465B (es) 2019-06-04

Similar Documents

Publication Publication Date Title
Konno et al. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
WO2014164533A8 (en) Methods of stereoselective synthesis of substituted nucleoside analogs
DOP2007000014A (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
UY32423A (es) Derivados de azaspiranil-alquilcarbamatos de 5 eslabones, su preparacion y su aplicacion en terapeutica
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
HRP20180976T1 (hr) Inhibitori iap
PE20080412A1 (es) Concentrados no acuosos de principios activos con efecto herbicida
ITMI20051779A1 (it) Processo migliorato per la produzione di derivati di acidi carbossilici saturi
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
ES2624961T3 (es) Síntesis de productos de péptido que contienen imida cíclica
UA111580C2 (uk) Кристалізація гідрохлориду 4'-епідаунорубіцину
CY1121286T1 (el) Βιομηχανικη διαδικασια για τη συνθεση οξεικης ουλιπρισταλης και του 4'-ακετυλ αναλογου αυτης
AR081659A1 (es) Procedimiento de obtencion de la forma cristalina ii del febuxostat
FI3461807T3 (fi) Uudenlaisten detergenttien suunnittelu ja kehitys pcr-järjestelmissä käyttöä varten
ATE504289T1 (de) Ausstossflüssigkeit und ausstossverfahren
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
ES2637984T3 (es) Composición cosmética para las uñas y utilización de derivado de isosorbida
RU2014124569A (ru) Способ выделения нуклеиновых кислот
MX2020004051A (es) Sintesis de icatibant.
UY35503A (es) Titulo: procedimiento de síntesis de derivados de la 7,8-dimetoxi-1,3 -dihidro-2h-3- benzazepin -2- ona y aplicación a la síntesis de la ivabradina
TH149057B (th) กระบวนการใหม่สำหรับการสังเคราะห์ของไอวาบราดีน (ivabradine) และ เกลือของมันจากการเติมด้วยกรดที่เป็นที่ยอมรับในทางเภสัชกรรม
TH127922A (th) กรรมวิธีสำหรับการเตรียมผลึกพื้นฐานเป็นแฟททิแอซิด เอสเทอร์